Principal Post

Business news & practical advice

ET

First routine NHS teplizumab dose given in Birmingham

By Laura Benning

Published Nov 18, 2026

Last checked: Nov 18, 2026.

This is general information, not medical advice.

No one in the UK had been given teplizumab through routine NHS care until a 42-year-old Shropshire woman began a two-week course at Birmingham's Queen Elizabeth Hospital, University Hospitals Birmingham said on Nov 5, 2026. Her diagnosis this summer was stage 2 type 1 diabetes, an early phase with no symptoms. Teplizumab is meant to delay the move to the stage where daily insulin is needed.

The trust said in June that a Birmingham teenager had received the drug before this through early access tied to a research study.

What teplizumab does

Type 1 diabetes happens when the immune system turns on the insulin-making cells of the pancreas. Teplizumab (brand name Tzield, made by Sanofi) latches onto a protein called CD3 on the immune cells behind that attack, according to the National Institute for Health and Care Excellence (NICE). NICE says this slows the harm done to those cells.

How type 1 diabetes develops

NICE describes the condition in three stages:

  1. Stage 1: the immune attack has begun and shows up in blood tests. Blood sugar stays normal, with no symptoms yet.
  2. Stage 2: the attack has moved further and blood sugar starts to shift, yet the person still has no symptoms.
  3. Stage 3: blood sugar climbs steeply and symptoms begin. This is when most diagnoses happen, and insulin is usually needed for life.

Teplizumab is for people at stage 2, aiming to put off stage 3.

Who can get it on the NHS

NICE's technology appraisal guidance TA1176, published July 9, 2026, recommends teplizumab for people who are 8 or older and whose diagnosis is stage 2 type 1 diabetes. The guidance applies in England, and NICE said patients in Wales would also get access.

An NHS children and young people's diabetes network lists the criteria. A person may qualify if they:

NICE says no national screening program exists for stage 2 at present. People usually find out through a research study, through testing because they are at higher risk, for example when a parent, brother, sister or child has the condition, or through tests done for another reason. Two UK studies screen for it: ELSA, for ages 2 to 17, and T1DRA, for adults aged 18 to 70.

How the treatment is given

According to NICE, teplizumab is dripped into a vein daily for 14 straight days. Every session takes 30 minutes or longer, and the dose is raised step by step early in the course. Patients attend hospital daily, weekends included, and the course is not repeated.

What the evidence shows

NICE's main evidence was TN-10, a clinical trial of 76 people, all 8 or older, who were at stage 2 and had a close relative who already had type 1 diabetes. Of these, 44 had teplizumab and 32 had a placebo. In that trial, NICE says, the drug held off symptomatic diabetes by about 32 months on average, close to three years.

What NICE says about side effects

According to NICE's guidance, adverse events (health problems logged during treatment) were reported more often in the TN-10 group that received teplizumab than in the placebo group. NICE's independent evidence reviewers said the drug appeared to raise the risk of infections and of conditions affecting the blood and lymph system, most notably a severe drop in neutrophils, a type of white blood cell. They also cautioned that, with so few participants, how the drug might affect immunity remained unclear. Clinical experts told NICE's committee that white blood cell levels, including neutrophils, were expected to return to normal during the two-week course. They described cytokine release syndrome, an immune reaction, as usually mild and mostly occurring in the first five days, when patients are in hospital and checked often.

What we know and what's next

Details on who qualifies are in NICE's guidance on teplizumab. For more stories, visit the Principal Post front page.

This is general information, not medical advice.

Originally reported by BBC News.

Sources

  1. University Hospitals Birmingham NHS Foundation Trust, "QEHB treats first UK patient with Teplizumab following NHS approval," Nov 5, 2026. https://www.uhb.nhs.uk/news-and-events/news/qehb-treats-first-uk-patient-with-teplizumab-following-nhs-approval/ (accessed Nov 18, 2026).
  2. NICE, "Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes," TA1176, published July 9, 2026. https://www.nice.org.uk/guidance/ta1176/chapter/1-Recommendation and https://www.nice.org.uk/guidance/ta1176 (accessed Nov 18, 2026).
  3. NICE news, "First disease-modifying therapy for NHS use to delay the onset of type 1 diabetes recommended," June 23, 2026. https://www.nice.org.uk/news/articles/teplizumab-to-delay-the-onset-of-type-1-diabetes-recommended (accessed Nov 18, 2026).
  4. NHS Children and Young People's Diabetes Network, FAQ. https://www.cypdiabetesnetwork.nhs.uk/national-network/faq/ (no date shown; accessed Nov 18, 2026).
  5. University Hospitals Birmingham, "Drug to delay Type 1 Diabetes approved for UK use," June 23, 2026. https://www.uhb.nhs.uk/news-and-events/news/drug-to-delay-type-1-diabetes-approved-for-uk-use/ (accessed Nov 18, 2026).
  6. NICE, TA1176, "3 Committee discussion" (adverse events paragraph), published July 9, 2026. https://www.nice.org.uk/guidance/ta1176/chapter/3-Committee-discussion (accessed Nov 18, 2026).
  7. BBC News, "First UK patient given groundbreaking diabetes drug," Nov 12, 2026. https://www.bbc.com/news/articles/c6e3dw88n9v1o (accessed Nov 18, 2026).

Back to the front page